(Investorideas.com
Newswire) a go-to platform for big investing ideas, including cannabis
stocks issues a news and trading alert for Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company
at the forefront of the cannabis, beverage, and wellness industries.
Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) has already had extreme volatility in early trading,
with a day’s range of $7.59 – 9.27. Stocks in the sector ran
yesterday and continued gain in early trading, but they are all
seeing red now. Tilray is currently trading at 7.69 -0.18(-2.29%).
Tilray today issued a statement applauding President Donald
Trump’s actions leading to the rescheduling of cannabis from
Schedule I to Schedule III under the Controlled Substances
Act—a defining inflection point that represents a fundamental
shift in U.S. drug policy, unlocking significant opportunities for
medical cannabis clinical research, patient access, and industry
standardization. The action represents the most consequential
federal cannabis policy development in decades, accelerating the
emergence of a regulated, science-driven medical cannabis framework
in the United States.
Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands,
stated:
“Today marks a pivotal moment for the United States. With
President Trump’s action to reschedule cannabis, federal
policy is finally aligning with science, medicine, and most
importantly, patient needs. This is about people: patients
fighting cancer, seniors managing chronic pain, veterans
navigating PTSD, and children with epilepsy whose families have
long sought safe, effective options. For decades, they have turned
to medical cannabis. Today, the system begins to catch up with
them. Rescheduling has the potential to accelerate clinical
research, broaden access, and elevate the quality, consistency,
and safety standards that establish medical cannabis as a
legitimate pillar of modern healthcare.”
“At Tilray, we have built a global platform for precisely
this moment. We are among the world’s largest cannabis
growers, with more than 7 million square feet of cultivation
capacity and a recognized global leader across
pharmaceutical-grade cannabis production, clinical research,
product innovation, and patient care. Through Tilray Medical, we
have served hundreds of thousands of patients across more than 20
countries in some of the world’s most stringently regulated
markets. This is how healthcare evolves. Tilray stands ready to
partner with regulators and healthcare providers to responsibly
expand access to medical cannabis and help shape the future of
this industry in the United States.”
Research cannabis stocks at Investorideas.com
https://www.investorideas.com/Marijuana-Stocks/stocks_list.asp
Sign up for free trading and stock news alerts at
Investorideas.com
Disclaimer/Disclosure:
Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does
not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly
regarding content and press release questions. More disclosure info:
https://www.investorideas.com/About/Disclaimer.asp
This article is a third party guest post published content and
not the content of Investorideas.com. Learn more about posting your
articles at
http://www.investorideas.com/Advertise/
Global investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
